Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study
Ana Westenberger,Volha Skrahina,Tatiana Usnich,Christian Beetz,Eva-Juliane Vollstedt,Björn-Hergen Laabs,Jefri J Paul,Filipa Curado,Snezana Skobalj,Hanaa Gaber,Maria Olmedillas,Xenia Bogdanovic,Najim Ameziane,Nathalie Schell,Jan Olav Aasly,Mitra Afshari,Pinky Agarwal,Jason Aldred,Fernando Alonso-Frech,Roderick Anderson,Rui Araújo,David Arkadir,Micol Avenali,Mehmet Balal,Sandra Benizri,Sagari Bette,Perminder Bhatia,Michael Bonello,Pedro Braga-Neto,Sarah Brauneis,Francisco Eduardo Costa Cardoso,Francesco Cavallieri,Joseph Classen,Lisa Cohen,Della Coletta,David Crosiers,Paskal Cullufi,Khashayar Dashtipour,Meltem Demirkiran,Patricia de Carvalho Aguiar,Anna De Rosa,Ruth Djaldetti,Okan Dogu,Maria Gabriela Dos Santos Ghilardi,Carsten Eggers,Bulent Elibol,Aaron Ellenbogen,Sibel Ertan,Giorgio Fabiani,Björn H Falkenburger,Simon Farrow,Tsviya Fay-Karmon,Gerald J Ferencz,Erich Talamoni Fonoff,Yara Dadalti Fragoso,Gençer Genç,Arantza Gorospe,Francisco Grandas,Doreen Gruber,Mark Gudesblatt,Tanya Gurevich,Johann Hagenah,Hasmet A Hanagasi,Sharon Hassin-Baer,Robert A Hauser,Jorge Hernández-Vara,Birgit Herting,Vanessa K Hinson,Elliot Hogg,Michele T Hu,Eduardo Hummelgen,Kelly Hussey,Jon Infante,Stuart H Isaacson,Serge Jauma,Natalia Koleva-Alazeh,Gregor Kuhlenbäumer,Andrea Kühn,Irene Litvan,Lydia López-Manzanares,McKenzie Luxmore,Sujeena Manandhar,Veronique Marcaud,Katerina Markopoulou,Connie Marras,Mark McKenzie,Michele Matarazzo,Marcelo Merello,Brit Mollenhauer,John C Morgan,Stephen Mullin,Thomas Musacchio,Bennett Myers,Anna Negrotti,Anette Nieves,Zeev Nitsan,Nader Oskooilar,Özgür Öztop-Çakmak,Gian Pal,Nicola Pavese,Antonio Percesepe,Tommaso Piccoli,Carolina Pinto de Souza,Tino Prell,Mark Pulera,Jason Raw,Kathrin Reetz,Johnathan Reiner,David Rosenberg,Marta Ruiz-Lopez,Javier Ruiz Martinez,Esther Sammler,Bruno Lopes Santos-Lobato,Rachel Saunders-Pullman,Ilana Schlesinger,Christine M Schofield,Artur F Schumacher-Schuh,Burton Scott,Ángel Sesar,Stuart J Shafer,Ray Sheridan,Monty Silverdale,Rani Sophia,Mariana Spitz,Pantelis Stathis,Fabrizio Stocchi,Michele Tagliati,Yen F Tai,Annelies Terwecoren,Sven Thonke,Lars Tönges,Giulia Toschi,Vitor Tumas,Peter Paul Urban,Laura Vacca,Wim Vandenberghe,Enza Maria Valente,Franco Valzania,Lydia Vela-Desojo,Caroline Weill,David Weise,Joanne Wojcieszek,Martin Wolz,Gilad Yahalom,Gul Yalcin-Cakmakli,Simone Zittel,Yair Zlotnik,Krishna K Kandaswamy,Alexander Balck,Henrike Hanssen,Max Borsche,Lara M Lange,Ilona Csoti,Katja Lohmann,Meike Kasten,Norbert Brüggemann,Arndt Rolfs,Christine Klein,Peter Bauer
DOI: https://doi.org/10.1093/brain/awae188
IF: 14.5
2024-08-01
Brain
Abstract:Estimates of the spectrum and frequency of pathogenic variants in Parkinson's disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has reached the clinical trial stage, a major obstacle in conducting these trials is that PD patients are largely unaware of their genetic status and, therefore, cannot be recruited. Expanding the number of investigated PD-related genes and including genes related to disorders with overlapping clinical features in large, well-phenotyped PD patient groups is a prerequisite for capturing the full variant spectrum underlying PD and for stratifying and prioritizing patients for gene-targeted clinical trials. The Rostock Parkinson's disease (ROPAD) study is an observational clinical study aiming to determine the frequency and spectrum of genetic variants contributing to PD in a large international cohort. We investigated variants in 50 genes with either an established relevance for PD or possible phenotypic overlap in a group of 12 580 PD patients from 16 countries [62.3% male; 92.0% White; 27.0% positive family history (FH+), median age at onset (AAO) 59 years] using a next-generation sequencing panel. Altogether, in 1864 (14.8%) ROPAD participants (58.1% male; 91.0% White, 35.5% FH+, median AAO 55 years), a PD-relevant genetic test (PDGT) was positive based on GBA1 risk variants (10.4%) or pathogenic/likely pathogenic variants in LRRK2 (2.9%), PRKN (0.9%), SNCA (0.2%) or PINK1 (0.1%) or a combination of two genetic findings in two genes (∼0.2%). Of note, the adjusted positive PDGT fraction, i.e. the fraction of positive PDGTs per country weighted by the fraction of the population of the world that they represent, was 14.5%. Positive PDGTs were identified in 19.9% of patients with an AAO ≤ 50 years, in 19.5% of patients with FH+ and in 26.9% with an AAO ≤ 50 years and FH+. In comparison to the idiopathic PD group (6846 patients with benign variants), the positive PDGT group had a significantly lower AAO (4 years, P = 9 × 10-34). The probability of a positive PDGT decreased by 3% with every additional AAO year (P = 1 × 10-35). Female patients were 22% more likely to have a positive PDGT (P = 3 × 10-4), and for individuals with FH+ this likelihood was 55% higher (P = 1 × 10-14). About 0.8% of the ROPAD participants had positive genetic testing findings in parkinsonism-, dystonia/dyskinesia- or dementia-related genes. In the emerging era of gene-targeted PD clinical trials, our finding that ∼15% of patients harbour potentially actionable genetic variants offers an important prospect to affected individuals and their families and underlines the need for genetic testing in PD patients. Thus, the insights from the ROPAD study allow for data-driven, differential genetic counselling across the spectrum of different AAOs and family histories and promote a possible policy change in the application of genetic testing as a routine part of patient evaluation and care in PD.